<DOC>
	<DOCNO>NCT01023295</DOCNO>
	<brief_summary>The primary objective study examine effect fosbretabulin tromethamine ( fosbretabulin ) PCV reflect change baseline number polypoid lesion indocyanine green angiography ( ICGA ) .</brief_summary>
	<brief_title>Study Evaluating Safety Response Fosbretabulin Asian Patients With Polypoidal Choroidal Vasculopathy ( PCV )</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>Inclusion Criteria Male female age ≥21 year . Asian race ( e.g . Chinese , Japanese , Korean , Thai ) . Polypoidal choroidal vasculopathy study eye Presence ≥ 1 visible polypoidal varicosity ICGA . Presence measurable branching vascular network BCVA ETDRS 68 4 letter study eye . Ophthalmologic Exclusion Criteria Prior treatment intravitreal systemic antiVEGF therapy within 60 day enrollment . Any prior treatment PCV include thermal laser photocoagulation , photodynamic therapy ( i.e. , verteporfin ) , investigational therapy . Any history prior retinal subretinal surgery , transpupillary thermography , radiation , implantation intravitreal drug delivery device , vitrectomy . Any intraocular surgery laser treatment within 90 day surgery plan study period . Fibrosis involve ≥50 % total lesion . Presence hemorrhage potentially obscure &gt; 75 % vascular pathology assess imaging procedure . Retinal choroidal vascular disease study eye due cause PCV , uveitis , trauma , pathologic myopia . Macular edema either eye due cause , diabetic retinopathy . Evidence glaucomatous eye disease , glaucomatous visual field loss . History allergy fluorescein ICG dye . Medical Exclusion Criteria Current history within two year significant heart disease . Uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Polypoidal Choroidal Vasculopathy</keyword>
	<keyword>PCV</keyword>
	<keyword>Polypoid</keyword>
	<keyword>oxigene</keyword>
	<keyword>VDA</keyword>
	<keyword>vascular disrupting agent</keyword>
	<keyword>combretastatin</keyword>
	<keyword>fosbretabulin</keyword>
</DOC>